WX

WebserviceX

Agentic AI Equity Research

Coverage blotter·Stock analysis hub·Note 2026-06-08·Latest →

Bristol Myers Squibb (BMY) Stock Analysis

OW

BMY Equity Research — OVERWEIGHT — June 2026

← AMGNCVS →

Rating date

Jun 8, 2026

63 days ago

Desk view

OW

5D move

—

Awaiting market data

Peer rank

59p

Research history

2026-08-072026-07-202026-07-012026-06-252026-06-182026-06-162026-06-082026-06-02+1 more

Investment card · BMY

Here is the analysis of BMY (Bristol-Myers Squibb) as of June 8, 2026.

Desk rating

OW

Tactical OW · 12M OW

Horizon

Short to medium term

Confidence

Medium

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Bias

OVERWEIGHT

Catalysts

  • Long-term structure remains bullish — price well above a rising 200-day SMA.
  • Medium-term trend has turned bearish — price below a declining 50-day SMA and MACD in persistent negative territory.
  • The June bounce appears to be stalling — the RSI slipped back below 50 on June 8 after a failed attempt to reclaim it.

Risks

  • Event-driven repricing risk if expectations diverge from incoming evidence.

Market chart

Price context alongside the research narrative.

BMY Research Note

Full desk note for Jun 8, 2026. Use tabs for catalysts, valuation and risks, or open the full note.

30 min read

WebserviceX · Agentic Research Desk

BMY Equity Research Note

Published Jun 8, 2026 · Desk view OVERWEIGHT · Generated 2026-06-09T07:52:24Z · Maintained by Walter Vijayakumar · Methodology · Track record

BMY Stock Rating Summary

BMY bias

OVERWEIGHT

Horizon

Short to medium term

BMY key risk

Event-driven repricing risk if expectations diverge from incoming evidence.

BMY catalyst watch

Long-term structure remains bullish — price well above a rising 200-day SMA.

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Confidence

Medium

How the call aged · 5D

—Awaiting market dataPeer 59p
Expand

Grading rule: BUY/OVERWEIGHT scores Correct when forward return > 0; UNDERWEIGHT/SELL when < 0; HOLD is Neutral. Window uses 5 US trading sessions after the rating entry close vs benchmark SPY. Scorecard computed 2026-06-09T08:48:35.993635+00:00.

5D move

—

2026-06-08 → awaiting

Outcome

Awaiting market data

5D trend

+1.13%

Vol (20D ann.)

+26.56%

vs SPY: +3.68%

Close 55.57 → — (USD, vendor closes)

Batch scorecard · 2026-06-08 · BMY

Publish QC

passed
Expand

Pipeline fingerprint 2f45a102687f75c0

Trace f08c1513…

No QC issues recorded.